Neogenomics (NEO) Capital Leases (2010 - 2026)

Neogenomics' (NEO) quarterly Capital Leases came in at $4.0 million in Q2 2026, up 14825.93% on a QoQ basis from $27000.0 in Q4 2025.

Neogenomics (NEO) Capital Leases (2010 - 2026) Analysis & Trends

Neogenomics (NEO) has 14 years of Capital Leases data on file, last reported at $4.0 million in Q2 2026.

Quarterly Capital Leases changed N/A year-over-year to $4.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.0 million (changed N/A YoY) and the FY2025 annual result came in at $27000.0, changed N/A from the prior year.
Capital Leases rose to $4.0 million in Q2 2026, from $27000.0 in the prior quarter.
In the past five years, Capital Leases ranged from a high of $4.0 million in Q2 2026 to a low of $27000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	234.15 Bn	230.09 Bn	8.34 Bn
2	Danaher	152.10 Bn	147.75 Bn	3.61 Bn
3	Natera	48.48 Bn	47.38 Bn	486.15 Mn
4	Agilent Technologies	44.35 Bn	42.55 Bn	990.00 Mn
5	Iqvia Holdings	43.68 Bn	41.60 Bn	1.44 Bn
6	Idexx Laboratories	43.02 Bn	42.83 Bn	779.09 Mn
7	Illumina	34.39 Bn	33.22 Bn	770.00 Mn
8	Mettler Toledo International	28.29 Bn	28.24 Bn	650.22 Mn
9	Labcorp Holdings	27.51 Bn	27.37 Bn	1.11 Bn
10	Neogenomics	2.42 Bn	2.28 Bn	91.88 Mn

Download Data